Summary of Use during Lactation

No information is available on the clinical use of rasbicurase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 34,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, the manufacturer recommends that breastfeeding be discontinued during rasburicase therapy and for 2 weeks after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Rasburicase

CAS Registry Number

134774-45-1

Drug Class

Breast Feeding

Lactation

Enzymes

Gout Suppressants

Urate Oxidase